Martin Shkreli, CEO of Turing Pharmaceuticals. (credit: NEPA Scene/Flickr)
Martin Shkreli, CEO of Turing Pharmaceuticals, just got a letter from the US Senate. And it’s not a nice letter (PDF).
It was sent by US Senators Susan Collins (R-Maine) and Claire McCaskill (D-Mo.), leaders of the Senate Special Committee on Aging, who are concerned by recent drug pricing practices. In addition to Shkreli, the senators sent letters to the heads of three other pharmaceutical companies, namely Valeant Pharmaceuticals, Retrophin, Inc., and Rodelis Therapeutics.
Recent actions within the pharmaceutical industry “have looked like little more than price gouging,” Sen. McCaskill noted in a press release. The release made particular note of Turing’s recent move to increase the price of the drug Daraprim from $13.50 a pill to $750.
Read 3 remaining paragraphs | Comments
No comments:
Post a Comment